M
Marko Spasic
Researcher at University of California, Los Angeles
Publications - 42
Citations - 5591
Marko Spasic is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 22 publications receiving 4366 citations.
Papers
More filters
Journal ArticleDOI
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh,Christina L. Harview,Jennifer H. Yearley,I. Peter Shintaku,Emma Taylor,Lidia Robert,Bartosz Chmielowski,Marko Spasic,Gina Henry,Voicu Ciobanu,Alisha N. West,Manuel Carmona,Christine Kivork,Elizabeth Seja,Grace Cherry,Antonio Gutierrez,Tristan Grogan,Christine Mateus,Gorana Tomasic,John A. Glaspy,Ryan O. Emerson,Harlan Robins,Robert H. Pierce,David Elashoff,Caroline Robert,Antoni Ribas +25 more
TL;DR: It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.
Journal ArticleDOI
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J Padrón,Deena M. Maurer,Mark H. O'Hara,Eileen M. O'Reilly,Robert A. Wolfe,O. Wainberg,Andrew H. Ko,George A. Fisher,Osama E. Rahma,Jaclyn P. Lyman,Christopher R. Cabanski,Jiajing Yu,Shannon M. Pfeiffer,Marko Spasic,Jingying Xu,Pier Federico Gherardini,Joyson Joseph Karakunnel,Rosemarie Mick,Cécile Alanio,Katelyn T. Byrne,Travis J. Hollmann,Jonni S. Moore,Derek D Jones,Marco Tognetti,Xiaoyong Yang,Lisa Salvador,E. John Wherry,Ute Dugan,Jill O'Donnell-Tormey,Lisa H. Butterfield,Vanessa M. Hubbard-Lucey,Ramy Ibrahim,J. Fairchild,Samantha L. Bucktrout,Theresa LaVallee,Robert H. Vonderheide +35 more
TL;DR: A randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC ( NCT03214250 ) was conducted as discussed by the authors .
Journal ArticleDOI
Characteristics and management of superior semicircular canal dehiscence.
TL;DR: Symptoms of superior semicircular canal dehiscence (SSCD) include autophony, inner ear conductive hearing loss, Hennebert sign, and sound-induced episodic vertigo and disequilibrium (Tullio phenomenon).
Journal ArticleDOI
Clinical outcomes of middle fossa craniotomy for superior semicircular canal dehiscence repair.
Lawrance K. Chung,Nolan Ung,Marko Spasic,Daniel T. Nagasawa,Panayiotis E. Pelargos,Kimberly Thill,Brittany L. Voth,Daniel Hirt,Quinton Gopen,Isaac Yang +9 more
TL;DR: Surgical repair of SSCD using a middle fossa craniotomy is associated with a high rate of symptom resolution and continued investigation using a larger patient cohort and longer-term follow-up could further demonstrate the effectiveness.
Journal ArticleDOI
CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
TL;DR: The authors discuss the complex regulation of CD133 expression in gliomas, its role in tumorigenesis, and its potential as a marker for targeted and personalized therapeutic intervention.